Patents by Inventor Christian Fiedler
Christian Fiedler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250188120Abstract: An affinity chromatographic method of preparing from an IgG-containing starting material an IgG formulation that includes one or more of IgG1, IgG2, IgG3 and IgG4 is provided. A method of the invention includes contacting the IgG-containing starting material with a first chromatographic medium including a first solid support having Protein A bound thereto, forming a Protein A bound fraction of an IgG subclass with Protein A binding affinity and forming a first flow through including an IgG subclass not binding to the Protein A; and contacting the first flow through with a first affinity ligand chromatographic medium including a second solid support having a first affinity ligand with IgG binding affinity bound thereto, forming a first affinity ligand-bound IgG subclass and a second flow through including an IgG subclass not bound to the first affinity ligand-bound IgG subclass.Type: ApplicationFiled: March 6, 2023Publication date: June 12, 2025Inventors: Christian Fiedler, Martin Purtscher, Lucia Gnauer
-
Patent number: 12257277Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) polysorbate 80 (PS80), and about 1% to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.Type: GrantFiled: January 13, 2023Date of Patent: March 25, 2025Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Eva Fritscher, Meinhard Hasslacher, Dominik Mittergradnegger, Tanvir Tabish
-
Patent number: 12246047Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.Type: GrantFiled: April 12, 2021Date of Patent: March 11, 2025Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Leopold Grillberger, Meinhard Hasslacher, Barbara Kraus, Dominik Mittergradnegger, Stefan Reuberger, Horst Schafhauser, Marian Bendik
-
Publication number: 20250002868Abstract: The present disclosure provides for a method of purifying adeno-associated virus comprising purifying full AAV capsids from a concentrated AAV fraction or preparation comprising empty AAV capsids and full AAV capsids. The present disclosure also provides for a method of purifying adeno-associated virus comprising purifying empty AAV capsids from a concentrated AAV fraction or preparation comprising empty AAV capsids and full AAV capsids. The method utilizes one or more monovalent and one or more divalent cations to effect the separation resulting in purified full AAV capsids or empty AAV capsids.Type: ApplicationFiled: August 3, 2022Publication date: January 2, 2025Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Dominik MITERGRADNEGGER, Meinhard HASSLACHER, Thomas GATTERNIG, Daniela VASINA, Michael FELDHOFER, Renate PFANDL
-
Patent number: 11981934Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken, and AAV is eluted from the affinity resin. Various buffers are disclosed for use in the wash steps and elution.Type: GrantFiled: December 27, 2018Date of Patent: May 14, 2024Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Meinhard Hasslacher, Jadranka Koehn
-
Publication number: 20230241139Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) polysorbate 80 (PS80), and about 1% to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.Type: ApplicationFiled: January 13, 2023Publication date: August 3, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian FIEDLER, Eva FRITSCHER, Meinhard HASSLACHER, Dominik MITTERGRADNEGGER, Tanvir TABISH
-
Publication number: 20230242897Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: ApplicationFiled: April 11, 2023Publication date: August 3, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Patent number: 11661593Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: GrantFiled: December 16, 2014Date of Patent: May 30, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Patent number: 11583563Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) polysorbate 80 (PS80), and about 1% to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.Type: GrantFiled: November 3, 2017Date of Patent: February 21, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Eva Fritscher, Meinhard Hasslacher, Dominik Mittergradnegger, Tanvir Tabish
-
Publication number: 20220267796Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken at room temperature, and AAV is eluted from the affinity resin at a lower temperature. Various buffers are disclosed for use in the wash steps and elution.Type: ApplicationFiled: June 26, 2020Publication date: August 25, 2022Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian FIEDLER, Marcus SCHEINDEL, Meinhard HASSLACHER, Jadranka KOEHN
-
Publication number: 20220041693Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: ApplicationFiled: February 8, 2021Publication date: February 10, 2022Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20210338752Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.Type: ApplicationFiled: April 12, 2021Publication date: November 4, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian FIEDLER, Leopold Grillberger, Meinhard Hasslacher, Barbara Kraus, Dominik Mittergradnegger, Stefan Reuberger, Horst Schafhauser, Marian Bendik
-
Publication number: 20210163990Abstract: The AAV compositions comprising an AAV and a buffer. These AAV compositions are appropriate for us in intracerebroventricular (ICV) and intraparenchymal (IPA) administration, as well as other routes of administration and can be provided in frozen, liquid or potentially freeze dried (lyophilized) state.Type: ApplicationFiled: July 11, 2019Publication date: June 3, 2021Applicants: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Eva FRITSCHER, Christian FIEDLER, Tanvir TABISH, Dominik MITTERGRADNEGGER, Stefan REUBERGER
-
Patent number: 11000561Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.Type: GrantFiled: November 3, 2017Date of Patent: May 11, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Leopold Grillberger, Meinhard Hasslacher, Barbara Kraus, Dominik Mittergradnegger, Stefan Reuberger, Horst Schafhauser, Marian Bendik
-
Patent number: 10934340Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: GrantFiled: March 20, 2019Date of Patent: March 2, 2021Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20200332266Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken, and AAV is eluted from the affinity resin. Various buffers are disclosed for use in the wash steps and elution.Type: ApplicationFiled: December 27, 2018Publication date: October 22, 2020Applicants: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Christian FIEDLER, Meinhard HASSLACHER, Jadranka KOEHN
-
Patent number: 10723761Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.Type: GrantFiled: June 6, 2017Date of Patent: July 28, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
-
Publication number: 20200018752Abstract: Provided herein are methods of measuring the qualitative and/or quantity attributes of gene therapy vector preparations. In certain embodiments, the gene therapy vector preparations are AAV preparations (e.g., AAV8). In certain embodiments the methods comprise determining the potency or dose of the AAV preparation using ELISA or ELISA in combination with CryoTEM.Type: ApplicationFiled: March 2, 2018Publication date: January 16, 2020Applicants: Baxalta Incorporated, Baxalta GmbHInventors: Marian BENDIK, Roman NECINA, Ernst BOEHM, Michael GRANINGER, Christian FIEDLER
-
Publication number: 20190382467Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: ApplicationFiled: March 20, 2019Publication date: December 19, 2019Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20190365835Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.Type: ApplicationFiled: November 3, 2017Publication date: December 5, 2019Applicants: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Christian FIEDLER, Leopold GRILLBERGER, Meinhard HASSLACHER, Barbara KRAUS, Dominik MITTERGRADNEGGER, Stefan REUBERGER, Horst SCHAFHAUSER, Marian BENDIK